GURUFOCUS.COM » STOCK LIST » USA » NAS » HilleVax Inc (NAS:HLVX) » Definitions » Earnings Yield (Joel Greenblatt) %
Switch to:

HilleVax Earnings Yield (Joel Greenblatt) %

: 0.00% (As of Dec. 2021)
View and export this data going back to 2022. Start your Free Trial

HilleVax's Enterprise Value for the quarter that ended in Dec. 2021 was $0.00 Mil. HilleVax does not have enough years/quarters to calculate its EBIT for the trailing twelve months (TTM) ended in Dec. 2021. Therefore, GuruFocus does not calculate HilleVax's Earnings Yield (Joel Greenblatt) at this moment.

The historical rank and industry rank for HilleVax's Earnings Yield (Joel Greenblatt) % or its related term are showing as below:

HLVX' s Earnings Yield (Joel Greenblatt) % Range Over the Past 10 Years
Min: -32.2   Med: 0   Max: 0
Current: -20.39

HLVX's Earnings Yield (Joel Greenblatt) % is ranked worse than
61.95% of 1561 companies
in the Biotechnology industry
Industry Median: -9.73 vs HLVX: -20.39

Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.

A better indicator of the attractiveness of an investment which takes growth into account is the Forward Rate of Return (Yacktman) %. HilleVax's Forward Rate of Return (Yacktman) % for the quarter that ended in Dec. 2021 was 0.00%. The Forward Rate of Return uses the normalized Free Cash Flow of the past seven years, and considers growth. The forward rate of return can be thought of as the return that investors buying the stock today can expect from it in the future.


HilleVax Earnings Yield (Joel Greenblatt) % Historical Data

The historical data trend for HilleVax's Earnings Yield (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

HilleVax Annual Data
Trend Dec20 Dec21
Earnings Yield (Joel Greenblatt) %
- -

HilleVax Semi-Annual Data
Dec20 Dec21
Earnings Yield (Joel Greenblatt) % - -

Competitive Comparison

For the Biotechnology subindustry, HilleVax's Earnings Yield (Joel Greenblatt) %, along with its competitors' market caps and Earnings Yield (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

HilleVax Earnings Yield (Joel Greenblatt) % Distribution

For the Biotechnology industry and Healthcare sector, HilleVax's Earnings Yield (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where HilleVax's Earnings Yield (Joel Greenblatt) % falls into.



HilleVax Earnings Yield (Joel Greenblatt) % Calculation

In his book, The Little That Beat the Market, hedge fund manager Joel Greenblatt defines Earnings Yield as operating income divided by enterprise value.

HilleVaxs Earnings Yield (Joel Greenblatt) for the fiscal year that ended in Dec. 2021 is calculated as

Earnings Yield (Joel Greenblatt)=EBIT/Enterprise Value
=-99.564/0
= %



HilleVax  (NAS:HLVX) Earnings Yield (Joel Greenblatt) % Explanation

Joel Greenblatt defines the earnings yield using the above equation because it more accurately reflects the company's profitability relative to its stock price. Items like interest payment and tax etc. are not directly related to the company's operational profitability.

Enterprise Value instead of market cap (share price) is used in the calculation because it is the real price stock and bond investors together pay for the company.


Be Aware

Joel Greenblatt's definition of earnings yield has the same problems the regular earnings yield does. It does not consider the growth of the company. It only looks at one-year's business operation. For cyclical companies, the earnings yield is usually highest at the peak of the business cycle. But these earnings are rarely sustainable.

Forward Rate of Return (Yacktman) % based on Don Yacktman's definition is a better measure of the expected rate of return for a stock.


HilleVax Earnings Yield (Joel Greenblatt) % Related Terms

Thank you for viewing the detailed overview of HilleVax's Earnings Yield (Joel Greenblatt) % provided by GuruFocus.com. Please click on the following links to see related term pages.


HilleVax Business Description

HilleVax logo
Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » HilleVax Inc (NAS:HLVX) » Definitions » Earnings Yield (Joel Greenblatt) %
Traded in Other Exchanges
N/A
Address
Website
Executives
Fhmls X, L.l.c. 10 percent owner 601 UNION STREET, SUITE 3200 TWO UNION SQUARE SEATTLE WA 98101
Dubin Gary director C/O HILLEVAX, INC. 75 STATE STREET, SUITE 100 - #9995 BOSTON MA 02109
Borkowski Astrid officer: Chief Medical Officer C/O HILLEVAX, INC. 75 STATE STREET, SUITE 100 - #9995 BOSTON MA 02109
Sepulveda Jaime director C/O HILLEVAX INC. 75 STATE STREET 100 - #9995 BOSTON MA 02109
Takeda Vaccines, Inc. 10 percent owner 75 SIDNEY STREET CAMBRIDGE MA 02139
Chu Shelley director ONE WINTHROP SQUARE SUITE 400 BOSTON MA 02110
Silbermann Susan Michele director C/O LIANBIO 103 CARNEGIE CENTER DRIVE, SUITE 215 PRINCETON NJ 08540
Fhmls X, L.p. 10 percent owner 601 UNION STREET, SUITE 3200 TWO UNION SQUARE SEATTLE WA 98101
Frazier Life Sciences X, L.p. 10 percent owner 601 UNION STREET, SUITE 3200 TWO UNION SQUARE SEATTLE WA 98101
Gerberding Julie L. director 2000 GALLOPING HILL ROAD KENILWORTH NJ 07033
Kohli Aditya director, officer: Chief Operating Officer C/O PHATHOM PHARMACEUTICALS, INC. 2150 E. LAKE COOK ROAD, SUITE 800 BUFFALO GROVE IL 60089
Socks David A officer: CFO & Chief Business Officer C/O CADENCE PHARMACEUTICALS, INC. 12481 HIGH BLUFF DRIVE, SUITE 200 SAN DIEGO CA 92130
Takeda Pharmaceutical Co Ltd 10 percent owner 1-1, NIHONBASHI-HONCHO 2-CHOME, CHUO-KU TOKYO M0 103-8668
Hershberg Robert director, officer: President and CEO 3005 FIRST AVENUE SEATTLE WA 98121
Topper James N 10 percent owner 550 HAMILTON AVENUE, SUITE 100 PALO ALTO CA 94301
Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)